Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics

RareCyte News

RareCyte® announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer
more →

RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP)
more →

Upcoming Events

Watch on demand an immersive webinar about RareCyte’s suite of applications in liquid biopsy and circulating tumor cell analysis.
more →

Pharma Programs

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

   – Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company
more →